In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Pharmaceutical
Japanese drugmaker Shionogi has entered into an option agreement with French firm Cilcare to acquire the exclusive license for the development, manufacturing, and commercialization of CIL001 and/or CIL003, a hearing loss treatment drug candidates worldwide. 8 June 2024
Pharmaceutical
Swiss pharma giant Roche on Friday announced new five-year data confirming the sustained efficacy and safety profile of Evrysdi (risdiplam) in children with Type 1 spinal muscular atrophy (SMA) from the open-label extension of the pivotal FIREFISH study. 8 June 2024
Pharmaceutical
Global biopharma firm Structure Therapeutics has announced the pricing of an expanded public offering, aiming to raise $476 million. 7 June 2024
Biotechnology
Microbiome therapeutics company Seres Therapeutics has announced a memorandum of understanding with Nestlé Health Science to sell its Vowst (fecal microbiota spores, live-brpk) assets. 7 June 2024
Biotechnology
I-Mab has appointed Phillip Dennis as chief medical officer, overseeing the company's global clinical development efforts. 7 June 2024
Biotechnology
USA-based immuno-oncology firm Marengo Therapeutics today announced a second strategic partnership with French drugmaker Ipsen to advance precision T cell engagers (TCEs) from Marengo’s next-generation TriSTAR platform. 7 June 2024
Biotechnology
Shares of Replimune closed up nearly 28% at $7.11 on Thursday after the company shared data on its oncolytic virus RP1 (vusolimogene oderparepvec), in combination with Bristol Myers Squibb’s Opdivo (nivolumab), 7 June 2024
Pharmaceutical
Abu Dhabi’s Department of Health has signed a Memorandum of Understanding (MoU) with AstraZeneca (LSE: AZN) to establish a world-class Rare Diseases Centre of Excellence (CoE) in the emirate. 7 June 2024
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim has reinforced previously announced data showing that adults treated with survodutide achieved statistically-significant improvement in metabolic dysfunction-associated steatohepatitis (MASH). 7 June 2024
Biotechnology
UK pharma major GSK has turned a research collaboration with Elsie Biotechnologies into a full takeover of the privately-held San Diago, USA- based biotech. 7 June 2024
Biotechnology
The US Food and Drug Administration (FDA) is to hold an advisory committee meeting on Monday to discuss whether data support a favorable benefit-risk assessment for the use of Eli Lilly’s donanemab for Alzheimer’s disease (AD). 7 June 2024
Biotechnology
Chicago, USA-based biopharma giant AbbVie has announced encouraging top-line results from its Phase II PICCOLO trial of Elahere (mirvetuximab soravtansine). 7 June 2024
Biotechnology
The recent approval by the US Food and Drug Administration (FDA) of Moderna’s (Nasdaq: MRNA) respiratory syncytial virus (RSV) vaccine mRESVIA represents a significant development in the field and will likely encourage the use of mRNA technology across other disciplines. 7 June 2024
Pharmaceutical
The US Food and Drug Administration (FDA) late Thursday announced the approved of Geron Corporation’s Rytelo (imetelstat), an oligonucleotide telomerase inhibitor. 7 June 2024
Pharmaceutical
Shares in Californian company Biomea Fusion were down almost 60% ahead of the opening bell on Friday, after news of a regulatory setback. 7 June 2024
Pharmaceutical
US healthcare giant Johnson & Johnson continued its M&A spending spree during May. 6 June 2024
Biotechnology
Moderna has announced that the US Food and Drug Administration has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. 6 June 2024
Biotechnology
UK-based AI-driven precision medicines company Exscientia today announced the appointment of two technology and clinical development leaders to senior roles. 6 June 2024
Biosimilars
Italy's Competition Authority (AGCM) is investigating four pharmaceutical companies over what it called coordination of their commercial strategies, allegedly delaying access to a biosimilar eye-disease treatment in the country. 6 June 2024
Biotechnology
Aurobindo Pharma's wholly-owned subsidiary, TheraNym Biologics Private, has signed a Master Service Agreement (MSA) with Merck Sharpe & Dohme (MSD). 6 June 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze